The DOI matches its Crossref record.
Tumour Hypoxia Affects the Responsiveness of Cancer Cells to Chemotherapy and Promotes Cancer Progression
Abstract
A solid tumour forms an organ-like structure that is comprised of cancer cells as well as stroma cells (fibroblasts, inflammatory cells) that are embedded in an extracellular matrix and are nourished by vascular network. However, tumoral microenvironment is heterogeneous due to the abnormal vasculature network and high proliferation rate of cancer cells. Because of these features, some regions are starved from oxygen, a phenomenon called hypoxia. Transient hypoxia is associated with inadequate blood flow while chronic hypoxia is the consequence of the increased oxygen diffusion distance due to tumour expansion. Both types of hypoxia are correlated with poor outcome for patients. Moreover, hypoxia also enhances chemoresistance of cancer cells. Firstly, the delivery of drugs in hypoxic area and cellular uptake of it are affected by hypoxia or associated acidity. Secondly, some chemotherapeutic drugs require oxygen to generate free radicals that contribute to cytotoxicity. Last, hypoxia induces cellular adaptations that compromise the effectiveness of chemotherapy. In response to nutrient deprivation due to hypoxia, the rate of proliferation of cancer cells decreases but chemotherapeutic drugs are more effective against proliferating cells. On the other hand, hypoxia induces adaptation by post-translational and transcriptional changes that promote cell survival and resistance to chemotherapy. Through these changes, hypoxia promotes angiogenesis, shift to glycolytic metabolism, expression of ABC transporters, cell survival by inducing the expression of genes encoding growth factors and the modulation of apoptotic process. The aim of this review is to provide a description of known hypoxia-induced mechanisms of chemoresistance at a cellular level.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Drug delivery and cellular uptake of drugs in hypoxic regions are known to be affected by hypoxia or associated acidity, resulting in the relative resistance of hypoxic tumor cells to chemotherapy. 376 , 377”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [376]
Citations
Cited by
Sorted by citations
Items 101–200 of 347
Maiorano, E., Regan, M. M., Viale, G., Mastropasqua, M. G., Colleoni, M. A., Castiglione‐Gertsch, M., Price, K. N., Gelber, R. D., Goldhirsch, A., & Coates, A. S. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0360-y · Cited by 51
“It may reflect poorer penetration of chemotherapeutic agents into micro-metastatic tumor deposits in tumors prone to show CNF, perhaps due to associated hypoxia (9, 11, 20-24) or some undefined cellular characteristic which reduces the efficacy of the chemotherapeutic agents”
The Interplay of Dysregulated pH and Electrolyte Imbalance in Cancer
Alfarouk, K. O., Ahmed, S. B. M., Ahmed, A., Elliott, R. L., Ibrahim, M. E., Ali, H. S., Wales, C. C., Nourwali, I., Aljarbou, A. N., Bashir, A. H. H., et al. (2020) · Cancers · doi:10.3390/cancers12040898 · Cited by 52
A Red‐Light‐Activated Ruthenium‐Caged NAMPT Inhibitor Remains Phototoxic in Hypoxic Cancer Cells
Lameijer, L. N., Ernst, D., Hopkins, S. L., et al. (2017) · Angewandte Chemie · doi:10.1002/ange.201703890 · Cited by 51
Valable, S., Petit, E., Roussel, S., Marteau, L., Toutain, J., Divoux, D., Sobrio, F., Delamare, J., Barré, L., & Bernaudin, M. (2011) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2011.01.010 · Cited by 51
Hypoxia Promotes Acquisition of Aggressive Phenotypes in Human Malignant Mesothelioma
Kim, M.-C., Hwang, S.-H., Kim, N.-Y., Lee, H.-S., Ji, S., Yang, Y., & Kim, Y. (2018) · BMC Cancer · doi:10.1186/s12885-018-4720-z · Cited by 49
Zhou, Y., Sun, K., Ma, Y., Yang, H., Zhang, Y., Kong, X., & Wei, L. (2014) · Scientific Reports · doi:10.1038/srep05382 · Cited by 49
The Development of Ru(II)-Based Photoactivated Chemotherapy Agents
Chen, Y., Bai, L., Zhang, P., Zhao, H., & Zhou, Q. (2021) · Molecules · doi:10.3390/molecules26185679 · Cited by 47
“Compared with traditional photodynamic therapy (PDT) [22,23], another phototherapy that is generally oxygen-dependent, PACT offers an oxygen-independent mechanism, and is therefore more suitable for hypoxic tumors, where the concentration of oxygen is remarkably low [24,25].”
BackgroundAzodyes as markers for tumor hypoxia imaging and therapy: An up-to-date review
KUMARI, R. R., Sunil, D., Ningthoujam, R. S., & Kumar, N. V. A. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.04.034 · Cited by 50
Qayum, N., Im, J. H., Stratford, M. R. L., Bernhard, E. J., McKenna, W. G., & Muschel, R. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1413 · Cited by 47
“Tumor hypoxia itself may also impede the action of some drugs and induce resistancemechanisms (5, 6).”
BackgroundPandey, N., Dhiman, S., Srivastava, T., & Majumder, S. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.06.006 · Cited by 47
“These hypoxic conditions are associated with tumor progression and chemoresistance as both the delivery of drug and its uptake by cells are affected by low oxygen tension [17].”
BackgroundKang, L., Fan, B., Sun, P., Huang, W., Jin, M., Wang, Q., & Gao, Z. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.08.029 · Cited by 47
SIRT1/PGC-1α/PPAR-γ Correlate With Hypoxia-Induced Chemoresistance in Non-Small Cell Lung Cancer
Xu, R., Luo, X., Ye, X., Li, H., Liu, H., Du, Q., & Zhai, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682762 · Cited by 44
“The hypoxic environment in solid tumors results from, among other factors, the rapid proliferation of tumor cells, leading to the depletion of available oxygen (21, 22).”
BackgroundA Mathematical Study of the Influence of Hypoxia and Acidity on the Evolutionary Dynamics of Cancer
Fiandaca, G., Delitala, M. E., & Lorenzi, T. (2021) · Bulletin of Mathematical Biology · doi:10.1007/s11538-021-00914-3 · Cited by 47
Hypoxia, Therapeutic Resistance, and Sphingosine 1-Phosphate
Cuvillier, O., Ader, I., Bouquerel, P., Brizuela, L., Gstalder, C., & Malavaud, B. A. (2013) · Advances in cancer research · doi:10.1016/b978-0-12-394274-6.00005-4 · Cited by 47
“The many effects of hypoxia on cancer biology include not only promo- tion of progression and metastasis (Lu & Kang, 2010; Sullivan & Graham, 2007) but also resistance to radiotherapy or chemotherapy (Cosse & Michiels, 2008; Rohwer & Cramer, 2011; Tredan, Galmarini, Patel, & Tannock, 2007).”
BackgroundSevere hypoxia induces chemo-resistance in clinical cervical tumors through MVP over-expression
Lara, P. C., Lloret, M., Clavo, B., Apolinario, R. M., Henríquez‐Hernández, L. A., Bordón, E., Fontes, F., & Rey, A. S. (2009) · Radiation Oncology · doi:10.1186/1748-717x-4-29 · Cited by 46
“Preclinical studies about the role of hypoxia in cancer cells showed that reduction of pO2 is a favoring factor to increase chemo-resistance [8,28].”
BackgroundYang, Q., Jiang, W., Zhuang, C., et al. (2015) · Oncology Reports · doi:10.3892/or.2015.4167 · Cited by 46
ABT-898 Induces Tumor Regression and Prolongs Survival in a Mouse Model of Epithelial Ovarian Cancer
Campbell, N., Greenaway, J. B., Henkin, J., & Petrik, J. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0402 · Cited by 44
“Tumor vasculature exhibits inefficient flow causing numerous hypoxic areas with limited blood supply (38, 39) resulting in suboptimal drug delivery that can facilitate drug resistance, allowing the tumor to persist and grow (40, 41).”
BackgroundHypoxia, hypoxia-inducible gene 2 (HIG2)/HILPDA, and intracellular lipolysis in cancer
Povero, D., Johnson, S. M., & Liu, J. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.06.013 · Cited by 46
Cosse, J.-P., Ronvaux, M., Ninane, N., Raes, M. J., & Michiels, C. (2009) · Neoplasia · doi:10.1593/neo.09632 · Cited by 44
“Besides its influence on the delivery and the uptake of chemotherapeutic drugs, hypoxia also affects the responsiveness of cancer cells to chemotherapy by inducing cellular adaptations through posttranslationalmodifications and gene expression regulation [2].”
Self-citationResearch progress in tumor angiogenesis and drug resistance in breast cancer
Mou, J., Li, C., Zheng, Q., Meng, X., & Tang, H. (2024) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0515 · Cited by 48
“Tumor cells typically undergo active DNA replication, and chemotherapy drugs act on the cell cycle 53 .”
BackgroundChemoresistance, Cancer Stem Cells, and miRNA Influences: The Case for Neuroblastoma
Buhagiar, A., & Ayers, D. (2015) · Analytical Cellular Pathology · doi:10.1155/2015/150634 · Cited by 44
Embryonic Protein Nodal Promotes Breast Cancer Vascularization
Quail, D. F., Walsh, L. A., Zhang, G., Findlay, S. D., Moreno, J. C. A., Fung, L. A., Ablack, A. L., Lewis, J. D., Done, S. J., Hess, D. A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3951 · Cited by 40
Monsurrò, V., Beghelli, S., Wang, R., Barbi, S., Coin, S., Pasquale, G. D., Bersani, S., Castellucci, M., Sorio, C., Eleuteri, S., et al. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-10 · Cited by 42
“From the gene ontology analysis it was interesting to observe the participation of hypoxia pathways in cancer cells with the “anti-viral” state as this can clearly affect tumor biology and responsiveness to chemotherapy [40] and likely immunotherapy of immune responsive cancers such as renal cell carcinoma [41] and me…”
BackgroundPDGF/PDGFR effects in osteosarcoma and the “add-on” strategy
Xu, J. H., Xie, L., & Guo, W. (2018) · Clinical Sarcoma Research · doi:10.1186/s13569-018-0102-1 · Cited by 41
The impact of preoperative anaemia and anaemic subtype on patient outcome in colorectal cancer
Tokunaga, R., Nakagawa, S., Miyamoto, Y., Ohuchi, M., Izumi, D., Kosumi, K., Taki, K., Higashi, T., Miyata, T., Yoshida, N., et al. (2018) · Colorectal Disease · doi:10.1111/codi.14425 · Cited by 41
Sheng, K. L., Kang, L., Pridham, K. J., Dunkenberger, L., Sheng, Z., & Varghese, R. T. (2020) · Scientific Reports · doi:10.1038/s41598-020-78126-3 · Cited by 43
Harper, K., Yatsyna, A., Charbonneau, M., Brochu‐Gaudreau, K., Perreault, A., Claudio Jeldres, A., McDonald, P. P., & Dubois, C. M. (2021) · Cancers · doi:10.3390/cancers13051093 · Cited by 43
Koltai, T. (2020) · European Journal of Clinical Nutrition · doi:10.1038/s41430-020-0684-6 · Cited by 40
Role of Carcinoma-Associated Fibroblasts and Hypoxia in Tumor Progression
Giaccia, A. J., & Schipani, E. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_73 · Cited by 43
Subhan, M. A. (2022) · RSC Advances · doi:10.1039/d2ra02005j · Cited by 42
Sun, H., Zhang, M., Cheng, K., Li, P., Han, S., Li, R., Su, M., Zeng, W., Liu, J., Guo, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12803 · Cited by 40
“The specific tumor microenvironment controls cell behavior and leads to stress responses, including glycolytic metabolism alteration, apoptosis, and angiogenesis [38].”
BackgroundClinical and Pre-clinical Methods for Quantifying Tumor Hypoxia
Rickard, A. G., Palmer, G. M., & Dewhirst, M. W. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12734-3_2 · Cited by 41
Fibrous stroma: Driver and passenger in cancer development
Sharma, V., Letson, J., & Furuta, S. (2022) · Science Signaling · doi:10.1126/scisignal.abg3449 · Cited by 38
“Second, increases in mechanical stress within a tumor, driven by CAF-derived ECM proteins and ECM-modifying enzymes, could collapse blood vessels, which not only impairs drug delivery but also causes hypoxia and subsequent acidosis that reduces the efficacy of anticancer drugs (216, 217).”
BackgroundAnticancer Drug Metabolism: Chemotherapy Resistance and New Therapeutic Approaches
Akhdar, H., Legendre, C., Aninat, C., & More, F. (2012) · InTech eBooks · doi:10.5772/30015 · Cited by 45
“Hypoxia and HIF-1 contribute to the poor response to anticancer therapy by several mechanisms (Cosse and Michiels, 2008; Tredan et al., 2007; Wouters et al., 2007).”
BackgroundMavroeidis, L., Sheldon, H., Briasoulis, E. C., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3059 · Cited by 39
“Considering the fact that hypoxia is the triggering factor of the evasive resistance to certain anti-angiogenic therapies (6-8) and it confers resistance to chemotherapy (9-11), we questioned whether severe hypoxia can mediate resistance to the anti-angiogenic action of metronomic vinorelbine.”
BackgroundHammer, S., Sommer, A., Fichtner, I., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2455 · Cited by 38
“Hypoxia triggers pathways that drive angiogenesis and tumor progression, and the presence of genes associated with these pathways has previously been associated with a negative prognosis and resistance to therapy (47, 48).”
BackgroundWang, W., Wu, C., Yang, C., et al. (2017) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2017.08.222 · Cited by 38
Designer Nanocarriers for Navigating The Systemic Delivery of Oncolytic Viruses
Howard, F. H. N., & Muthana, M. (2019) · Nanomedicine · doi:10.2217/nnm-2019-0323 · Cited by 38
Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer
Nath, A., Mitra, S., Mistry, T., Pal, R., & Nasare, V. D. (2021) · Medical Oncology · doi:10.1007/s12032-021-01610-x · Cited by 41
Kumar, A., D'Souza, S. S., Nagaraj, S. R. M., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0992-y · Cited by 38
Ca2+ Signalling and Hypoxia/Acidic Tumour Microenvironment Interplay in Tumour Progression
Audero, M. M., Prevarskaya, N. B., & Fiorio, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137377 · Cited by 40
“Hypoxia also plays a key role in chemoresistance, as reduced oxygen availability can affect not only drug delivery but also chemotherapeutics activity [27].”
BackgroundTargeting Hypoxia-Inducible Factor-1α for the Management of Hepatocellular Carcinoma
Huynh, K. N., Rao, S. S., Roth, B. J., Bryan, T., Fernando, D. M., Dayyani, F., Imagawa, D. K., & Abi‐Jaoudeh, N. (2023) · Cancers · doi:10.3390/cancers15102738 · Cited by 36
“In addition, acute hypoxic cells are considered resistant to chemotherapy and radiation therapy, rendering these therapies ineffective at destroying cancerous cells [17,21,22].”
BackgroundMao, X.-W., Nanzhang, Xiao, J., Wu, H., & Ding, K. (2021) · Journal of Immunology Research · doi:10.1155/2021/8887437 · Cited by 39
Cheng, Y.-C., Liou, J., Kuo, C., Lai, W.-Y., Shih, K.-H., Chang, C.-Y., Pan, W., Tseng, J. T.-C., & Chang, J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0778 · Cited by 36
“, are responsible for cancer cells developing drug resistance (1, 2).”
Backgroundda Rocha, H. L., Godet, I., Kurtoglu, F., Metzcar, J., Konstantinopoulos, K., Bhoyar, S., Gilkes, D. M., & Macklin, P. (2021) · iScience · doi:10.1016/j.isci.2021.102935 · Cited by 35
Hypoxia-inducible factor-1α expression indicates poor prognosis in myelodysplastic syndromes
Tong, H., Hu, C., Zhuang, Z., Wang, L., & Jin, J. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.696637 · Cited by 36
Dower, C. M., Bhat, N., Wang, W., & Wang, H. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3458 · Cited by 35
“Metastasis is a multistep process that involves: (1) intravasation of tumor cells into the blood stream or lymphatic circulation, (2) survival of tumor cells in circulation, (3) extravasation out of the blood stream, and (4) engraftment and growth at the secondary site.”
BackgroundNanotechnology‐mediated photodynamic therapy: Focus on overcoming tumor hypoxia
Moloudi, K., Abrahamse, H., & George, B. P. A. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1937 · Cited by 34
OuYang, P., Su, Z. Z., Mao, Y., Liang, X.-X., Liu, Q., Deng, W., & Xie, F. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0546 · Cited by 34
“Furthermore, tumor hypoxia has been acknowledged to affect the responses toboth radiotherapy (38) and chemotherapy (39), and has been associated with poorer”
BackgroundMethyl syringate, a TRPA1 agonist represses hypoxia-induced cyclooxygenase-2 in lung cancer cells
Park, J., Shim, M. K., Jin, M., Rhyu, M., & Lee, Y. (2016) · Phytomedicine · doi:10.1016/j.phymed.2016.01.009 · Cited by 33
Bioengineered smart bacterial carriers for combinational targeted therapy of solid tumours
Alizadeh, S., Esmaeili, A., Barzegari, A., Rafi, M. A., & Omidi, Y. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1737087 · Cited by 33
Autophagy and TrkC/NT-3 signaling joined forces boost the hypoxic glioblastoma cell survival
Jawhari, S., Bessette, B., Hombourger, S., Durand, K., Lacroix, A., Labrousse, F., Jauberteau, M., Ratinaud, M., & Verdier, M. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx029 · Cited by 34
Liu, Y., Jing, J., Jia, F., Su, S., Tian, Y., Gao, N., Yang, C., Zhang, R., Wang, W., & Zhang, X. (2020) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b22097 · Cited by 33
Si, Y., Zhang, Y., Guan, J.-S., Ngo, H. G., Totoro, A., Singh, A. P., Chen, K., Xu, Y., Yang, E. S.-H., Zhou, L., et al. (2021) · Vaccines · doi:10.3390/vaccines9080882 · Cited by 32
“However, TNBCs usually develop drug resistance and result in distant metastasis post primary treatment and chemotherapy, which could be caused by ATP-binding cassette transporters-mediated drug efflux [5–7], cancer stem cells [8,9], hypoxia [10,11], dysregulation of apoptosis [12,13], heterogeneity [14,15], activation…”
BackgroundChe-1 sustains hypoxic response of colorectal cancer cells by affecting Hif-1α stabilization
Bruno, T., Valerio, M., Casadei, L., Nicola, F. D., Goeman, F., Pallocca, M., Catena, V., Iezzi, S., Sorino, C., Desantis, A., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0497-1 · Cited by 31
“Hypoxia is one of the most important pathological characteristics of solid tumors, and is clinically associated with a poor prognosis as it may adversely affect the outcome of radiotherapy and chemotherapy [37, 38].”
Zhang, L.-L., Zhou, G., Li, Y., Tang, L., Mao, Y., Lin, A., Ma, J., Qi, Z., & Sun, Y. H. (2017) · Cancer Medicine · doi:10.1002/cam4.1233 · Cited by 31
“Tumor hypoxia is key factor in development of radioand chemoresistance [9, 10].”
BackgroundZhang, L.-L., Li, Y.-Y., Hu, J., Zhou, G., Chen, L., Li, W., Lin, A.-H., Ma, J., Qi, Z., & Sun, Y. H. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2017.359 · Cited by 30
Macklin, P. S., Yamamoto, A., Browning, L., Hofer, M., Adam, J., & Pugh, C. W. (2020) · The Journal of Pathology · doi:10.1002/path.5402 · Cited by 33
“Chemotherapy may be less effective due to reduced responsiveness of hypoxic tumour cells to cytotoxins [35].”
BackgroundSun, X., Luo, H., Chenbo, H., Zhang, Y., & Yan, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.700062 · Cited by 31
“Targeting hypoxia will thus inhibit several traits of tumor progression, metastasis , radioresistance, and chemoresistance (10, 11), which has been an important focus of TNBC therapy.”
BackgroundThe Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia
Gallez, B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.853568 · Cited by 35
“We have already discussed that HIF-mediated cellular processes may alter cell apoptosis, autophagy and tumor stemness which can have a direct impact on the drug response (Cosse and Michiels, 2008; Das et al., 2008; Rohwer and Cramer, 2011).”
BackgroundRole of heparan sulfatases in ovarian and breast cancer.
Khurana, A., Beleford, D. T., He, X., CHIEN, J. R., & Shridhar, V. (2013) · Europe PMC (PubMed Central) · Cited by 32
Simončič, U., Leibfarth, S., Welz, S., Schwenzer, N. F., Schmidt, H., Reischl, G., Pfannenberg, C., la Fougère, C., Nikolaou, K., Zips, D., et al. (2017) · Medical Physics · doi:10.1002/mp.12228 · Cited by 30
Squillante, M. R., Jüstel, T., Anderson, R. R., Brecher, C., Chartier, D., Christian, J. F., Cicchetti, N., Espinoza, S., McAdams, D. R., Müller, M., et al. (2018) · Optical Materials · doi:10.1016/j.optmat.2018.04.033 · Cited by 30
Tian, N., Feng, Y., Sun, W., et al. (2019) · Dalton Transactions · doi:10.1039/c9dt00441f · Cited by 30
Folic acid-modified phthalocyanine-nanozyme loaded liposomes for targeted photodynamic therapy
Nwahara, N., Abrahams, G. L., Prinsloo, E., & Nyokong, T. (2021) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2021.102527 · Cited by 31
Post-Hypoxic Cells Promote Metastatic Recurrence after Chemotherapy Treatment in TNBC
Godet, I., Mamo, M., Thurnheer, A., Rosen, D. M., & Gilkes, D. M. (2021) · Cancers · doi:10.3390/cancers13215509 · Cited by 32
“The rapid proliferation of cancer cells along with the lack of efficient vasculature causes regions of hypoxia to develop in 90% of solid tumors [15,16].”
Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal
Espejo-Cruz, M. L., González‐Rubio, S., Zamora, J., Amado, V., Alejandre, R., Sánchez‐Frías, M., Ciria, R., de la Mata, M., Rodríguez‐Perálvarez, M., & Ferrín, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313073 · Cited by 32
Hypoxia Changes Energy Metabolism and Growth Rate in Non-Small Cell Lung Cancer Cells
Nisar, H., González, P. M. S., Brauny, M., Labonté, F. M., Schmitz, C., Roggan, M. D., Konda, B., & Hellweg, C. E. (2023) · Cancers · doi:10.3390/cancers15092472 · Cited by 31
“This may be chronic (diffusion-limited), due to increasing distances between the proliferating tumor cells and the feeding vessel, or it may be acute (perfusionlimited), due to the poor architecture of the feeding vessel periodically resulting in its collapse [1,2].”
BackgroundGolan, M., & Mabjeesh, N. J. (2013) · Cell Cycle · doi:10.4161/cc.25379 · Cited by 30
“Most human cancers exhibit permanent or transient hypoxia.(11) Hypoxia has a major role in cancer progression and angiogenesis.”
BackgroundCD73; a key ectonucleotidase in the development of breast cancer: Recent advances and perspectives
Soleimani, A., Taghizadeh, E., Shahsavari, S., Amini, Y., Rashidpour, H., Azadian, E., Jafari, A., Parizadeh, M. R., Mashayekhi, K., Soukhtanloo, M., et al. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28187 · Cited by 28
“Solid tumors, such as breast tumor due to heterogeneity and complexity in their composition are an organ‐ like structure containing malignant and stromal cells, which are located in the extracellular matrix (ECM) and supplied via a vascular network (Cosse & Michiels, 2008; Gao, Dong, & Zhang, 2014).”
BackgroundIikuni, S., Okada, Y., Shimizu, Y., Watanabe, H., & Ono, M. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00953 · Cited by 29
Gariboldi, M. B., Taìana, E., Bonzi, M. C., Craparotta, I., Giovannardi, S., Mancini, M., & Monti, E. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.05.008 · Cited by 29
Zuo, X., Li, L., & Sun, L. V. (2020) · Journal of Receptors and Signal Transduction · doi:10.1080/10799893.2020.1808679 · Cited by 27
“Hypoxia refers to a condition of low oxygen tension in tissues and has emerged as an adverse factor in cancer development and associated with poor outcome regardless of treatment modality [13,14].”
Backgroundde Lima, R. G., Tedesco, A. C., da Silva, R. S., & Lawrence, M. J. (2017) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2017.05.013 · Cited by 29
“Introduction In a solid tumor, the high rate of cell proliferation and abnormal vasculature network result in a highly heterogeneous microenvironment which means that some regions of the tumor are well perfused while others are starved of oxygen - a phenomenon called as hypoxia [1-2].”
BackgroundHong, B., Lui, V. W. Y., Hui, E. P., Ng, M. H. L., Cheng, S.-H., Sung, F. L., Tsang, C., Tsao, S., & Chan, A. T. �. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9356-z · Cited by 27
“The lack of oxygen in the inner core of solid tumors, primarily due to the diffusion limit from blood vessels and the formation of aberrant tumor blood vessel thus poor blood flow, is believed to contribute to tumor progression and resistance to conventional radiotherapy and chemotherapy [4, 5].”
BackgroundCosse, J.-P., Rommelaere, G., Ninane, N., Arnould, T., & Michiels, C. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.07.009 · Cited by 26
“Besides direct effects, hypoxia also promotes cancer cell resistance against chemotherapy by inducing adaptive mechanisms to hypoxia [4].”
BackgroundSelf-citationCell intrinsic and extrinsic regulation of leukemia cell metabolism
Jiang, Y., & Nakada, D. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-1958-6 · Cited by 26
“Conventional chemotherapies induces oxidative stress, and tumors in hypoxic regions are protected from chemotherapy-induced oxidative stress [116].”
Xu, J., Wan, Y., Tang, F., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.720474 · Cited by 25
Huang, J., Lu, Z., Xiao, Y., et al. (2018) · Medical Science Monitor · doi:10.12659/msm.908553 · Cited by 25
“Finally, hypoxia promotes tumor cells at a low proliferation rate and becomes insensitive to the pressure of apoptosis [4].”
BackgroundMetal/Metal Oxide Nanoparticles for Cancer Therapy
Vinardell, M. P., & Mitjans, M. (2018) · Nanomedicine and nanotoxicology · doi:10.1007/978-3-319-89878-0_10 · Cited by 25
Mirzaei, S., Ranjbar, B., Tackallou, S. H., & Aref, A. R. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154676 · Cited by 28
Hylander, B. L., Sen, A., Beachy, S. H., Pitoniak, R., Ullas, S., Gibbs, J. F., Qiu, J., Prey, J. D., Fetterly, G. J., & Repasky, E. A. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.047 · Cited by 25
“It is known that tumors develop mechanisms to survive hypoxic microenvironments and these mechanisms contribute to the ability of tumor cells to survive chemotherapy (see reviews [52, 53]) so this reduction in hypoxia may very well be an additional factor contributing to increased response to chemotherapy.”
BackgroundEarly pregnancy on the diaphragm with endometriosis.
Norenberg, D. D., Gundersen, J. H., Janis, J. F., & Gundersen, A. L. (1977) · PubMed · Cited by 27
Bong, J. W., Gim, J., Ju, Y., Cheong, C., Lee, S.-I., Oh, S.-C., Min, B.-W., & Kang, S. (2022) · Cancers · doi:10.3390/cancers14051297 · Cited by 27
Bisceglie, F., Alinovi, R., Pinelli, S., Galetti, M., Pioli, M., Tarasconi, P., Mutti, A., Goldoni, M., & Pelosi, G. (2016) · Metallomics · doi:10.1039/c6mt00170j · Cited by 24
Biomaterials to suppress cancer stem cells and disrupt their tumoral niche.
Garcia-Mazas, C., Csaba, N., & Garcia-Fuentes, M. (2017) · International journal of pharmaceutics · doi:10.1016/j.ijpharm.2016.12.013 · Cited by 19
AEG-1 is involved in hypoxia-induced autophagy and decreases chemosensitivity in T-cell lymphoma
Yan, J., Zhang, J., Zhang, X., Li, X., Li, L., Li, Z., Chen, R., Zhang, L., Wu, J., Wang, X., et al. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0033-6 · Cited by 22
Dong-feng, H., Ma, D., & Erhu, J. (2012) · Clinical Breast Cancer · doi:10.1016/j.clbc.2011.11.002 · Cited by 22
Development of the Implantable Resonator System for Clinical EPR Oximetry
Caston, R. M., Schreiber, W. A., Hou, H. G., et al. (2017) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-017-0809-2 · Cited by 21
“Hypoxia can also decrease the effectiveness of chemotherapy and immunotherapy [2, 3].”
Glück, A. A., Orlando, E., Leiser, D., Turan, M. P., Nisa, L., Quintin, A., Gavini, J., Stroka, D., Berezowska, S., Bubendorf, L., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0256-6 · Cited by 22
Iancu, C. V., Bocci, G., Ishtikhar, M., Khamrai, M., Oreb, M., Oprea, T. I., & Choe, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-05383-9 · Cited by 24
Lowerison, M. R., Zhang, Y., Chen, X., Fan, T. M., & Song, P. (2021) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2021.3119280 · Cited by 21
“The addition of AA agents is thought to be essential to the efficacy of this combined therapy in part via the phenomenon of vascular normalization [7], where the selective remodeling of chaotic intratumoral vasculature can alleviate interstitial hypertension, improving blood flow and the delivery of chemotherapeutics…”
BackgroundApplication of Stem Cells in Targeted Therapy of Breast Cancer: A Systematic Review
Madjd, Z., Gheytanchi, E., Erfani, E., & Asadi‐Lari, M. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.5.2789 · Cited by 21
“In line with the second model, various studies have shown that cell stressors such as hypoxia, which are capable in inducing cancer aggression and MDR phenotypes, also increase stem-like properties (Harris, 2002; Semenza, 2003; Cosse and Michiels, 2008; Han et al., 2008; Semenza, 2008).”
ResultTopkan, E., Ekici, N. Y., Özdemir, Y., Beşen, A. A., Yıldırım, B. A., Mertsoylu, H., Sezen, D., & Selek, U. (2019) · The International Journal of Biological Markers · doi:10.1177/1724600818821688 · Cited by 21
Jin, Z., Zhao, Q., Yuan, S., Jiang, W., & Hu, Y. (2021) · Macromolecular Bioscience · doi:10.1002/mabi.202100092 · Cited by 19
Bodalal, Z., Bogveradze, N., ter Beek, L. C., van den Berg, J. G., Sanders, J., Hofland, I., Trebeschi, S., Lipman, K. B. W. G., Storck, K., Hong, E. K., et al. (2023) · Insights into Imaging · doi:10.1186/s13244-023-01474-x · Cited by 22
Ghosh, S., Jawed, J. J., Halder, K., Banerjee, S., Chowdhury, B. P., Saha, A., Juin, S. K., Majumdar, S. B., Bose, A., Baral, R., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26478 · Cited by 19
“So, generation of hypoxic conditions in vitro can successfully mimic the tumor core regulations [41, 42].”
BackgroundChung, C. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa308 · Cited by 19
Krawczyk, M. A., Styczewska, M., Sokolewicz, E. M., Kunc, M., Gabrych, A., Fatyga, A., Iżycka‐Świeszewska, E., Kazanowska, B. J., Adamkiewicz-Drożyńska, E., & Bień, E. (2019) · Biomarkers · doi:10.1080/1354750x.2019.1606275 · Cited by 17
“…demonstrate more malignant phenotypes and resistance to CHT and RTX. Reduced sensitivity to CHT is associated with limited activation and penetration of the cytostatic drug to poorly vascularised regions and induction of the multidrug resistance (Brown and Wilson 2004, Cosse and Michiels 2008).”
BackgroundMittal, S., & Mallia, M. B. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106687 · Cited by 19
Metadata
- Authors
- Cosse, J.-P., & Michiels, C.
- Affiliations
- University of Namur (BE)
- Corresponding author
- Michiels, Carine
- ORCID
- Michiels, Carine
- Venue
- Anti-Cancer Agents in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-10-01
- Volume
- 8
- Issue
- 7
- Pages
- 790-797
- ISSN
- 1568-0118 (ISSN-L)
- 1871-5206
- OpenAlex
- W2044149912
- Cited by
- 348
- References
- 0
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 16 · 2023: 19 · 2022: 27 · 2021: 32 · 2020: 33 · 2019: 21 · 2018: 24 · 2017: 23 · 2016: 25 · 2015: 25 · 2014: 15 · 2013: 20 · 2012: 14
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Anti-Cancer Agents in Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- Repository of the University of Namur (submittedVersion)
- Funders
- Fonds De La Recherche Scientifique - FNRS
- Fonds pour la Formation à la Recherche dans l’Industrie et dans l’Agriculture
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- tumor hypoxia, chemoresistance, tumor microenvironment, tumor stroma, tumor vasculature, transcriptional adaptation, angiogenesis, glycolytic metabolism, ABC transporters, apoptosis, tumor progression
- MeSH terms
- Animals, Autophagy, Humans, Neoplasm Invasiveness, Neoplasms, Neovascularization, Pathologic, Cell Hypoxia, Tumor Suppressor Protein p53, Disease Progression, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-bcl-2, Angiogenesis Inhibitors, Cell Proliferation, Hypoxia-Inducible Factor 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
